Next-generation immunotherapy beyond PD-1 in China — the Chinese pharmaceutical industry's development of novel immunotherapy targets including LAG-3, TIM-3, TIGIT, VEGF/PD-1 bispecifics, CD47, and cellular immunotherapy advancing beyond the first-generation PD-1/PD-L1 checkpoint inhibitor paradigm — creates the future commercial market for Chinese immunotherapy, with the China...
Italiano 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt